Following a limited submission
AWMSG advice |
|
| Status: Recommended | |
Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) is recommended as an option for use within NHS Wales for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|
Medicine details |
|
| Medicine name | doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo®) |
| Formulation | 100 mg/ 300 mg/ 245 mg film-coated tablet |
| Reference number | 3648 |
| Indication | Treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Infections |
| Submission type | Limited |
| Status | Recommended |
| Advice number | 1020 |
| NMG meeting date | 22/07/2020 |
| AWMSG meeting date | 15/09/2020 |
| Date of issue | 24/09/2020 |
| Commercial arrangement | WPAS |